POSEIDA THERAPEUTICS INC (PSTX) Stock News

USA - NASDAQ:PSTX - US73730P1084 - Common Stock

9.5 USD

-0.06 (-0.63%)

Last: 1/7/2025, 8:07:14 PM

9.54 USD

+0.04 (+0.42%)

After Hours: 1/7/2025, 8:07:14 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PSTX Latest News, Press Relases and Analysis

All

Press Releases

9 months ago - By: Halper Sadeh LLC

PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders

9 months ago - By: Halper Sadeh LLC - Mentions: PWOD RVNC B

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PWOD, RVNC, B, PSTX on Behalf of Shareholders

9 months ago - By: Halper Sadeh LLC - Mentions: B ZUO

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, ZUO, PSTX on Behalf of Shareholders

10 months ago - By: Benzinga

Where Poseida Therapeutics Stands With Analysts

a year ago - By: BusinessInsider

News Image

PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024

9 months ago - By: Brodsky & Smith LLC - Mentions: PTVE IPG OMC

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pactiv Evergreen Inc. (Nasdaq – PTVE), Enterprise Bancorp, Inc. (Nasdaq Global Select Market – EBTC), The Interpublic Group of Companies, Inc. (NYSE – IPG), Poseida

9 months ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

10 months ago - By: Halper Sadeh LLC - Mentions: AVTE GATO

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, AVTE, GATO on Behalf of Shareholders

10 months ago - By: Brodsky & Smith LLC - Mentions: GATO MPAD AVTE

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Poseida Therapeutics, Inc. (Nasdaq – PSTX), Gatos Silver, Inc. (NYSE - GATO), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc. (Nasdaq - AVTE)

10 months ago - By: Benzinga - Mentions: BSX DHR LLY MDT ...

10 Health Care Stocks With Whale Alerts In Today's Session

10 months ago - By: Kahn Swick & Foti, LLC

POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX

10 months ago - By: Halper Sadeh LLC - Mentions: ZUO MNTX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, ZUO, MNTX on Behalf of Shareholders

10 months ago - By: Brodsky & Smith LLC - Mentions: ATSG MPAD AVTE

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Poseida Therapeutics, Inc. (Nasdaq – PSTX), Air Transport Services Group, Inc. (Nasdaq– ATSG), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc.

10 months ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

10 months ago - By: Halper Sadeh LLC

PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders

10 months ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

10 months ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

10 months ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

11 months ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

a year ago - By: MaxCyte, Inc - Mentions: MXCT CERT

MaxCyte Appoints Cynthia Collins to its Board of Directors

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics to Present at Upcoming Investor Conferences

a year ago - By: InvestorPlace

PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024

a year ago - By: Poseida Therapeutics, Inc.

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024